Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months –
These Biotechs and IPOs Inspire Big Insider Buying
08:15am, Sunday, 28'th Apr 2024
As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Apr 2024
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
07:00am, Tuesday, 02'nd Apr 2024
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 18'th Mar 2024
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
10:31am, Thursday, 07'th Mar 2024
While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its k
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
07:00am, Thursday, 07'th Mar 2024
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical tr
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
07:00am, Monday, 04'th Mar 2024
– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
11:01am, Thursday, 29'th Feb 2024
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
09:51am, Thursday, 29'th Feb 2024
EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
07:00am, Thursday, 29'th Feb 2024
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 27'th Feb 2024
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Is Betting The Bank On EYP-1901
08:36am, Wednesday, 21'st Feb 2024
EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 16'th Feb 2024
WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
01:00pm, Thursday, 15'th Feb 2024
Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
